The Technical Analyst
Select Language :
Celcuity Inc [CELC]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Celcuity Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Celcuity Inc is listed at the  Exchange

3.65% $18.16

America/New_York / 27 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 439.53 mill
EPS: -2.74
P/E: -6.63
Earnings Date: Mar 27, 2024
SharesOutstanding: 24.20 mill
Avg Daily Volume: 0.213 mill
RATING 2024-03-27
B-
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Sell
Return On Asset: Sell
DE: Buy
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -6.63 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.13x
Company: PE -6.63 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$1.278
(-92.96%) $-16.88
Date: 2024-03-28
Expected Trading Range (DAY)

$ 17.27 - 19.05

( +/- 4.91%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-18 Sullivan Brian F. Buy 765 897 Common Stock
2024-03-18 Sullivan Brian F. Sell 765 897 Common Stock
2024-02-21 Buller Richard E Sell 350 Common Stock
2024-02-13 Hahne Vicky Buy 5 530 Stock Option (right to buy)
2024-02-13 Laing Lance G. Buy 7 765 Stock Option (right to buy)
INSIDER POWER
9.34
Last 100 transactions
Buy: 4 076 997 | Sell: 2 930 046

Forecast: 16:00 - $18.16

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $18.16
Forecast 2: 16:00 - $18.16
Forecast 3: 16:00 - $18.16
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $18.16 (3.65% )
Volume 0.193 mill
Avg. Vol. 0.213 mill
% of Avg. Vol 90.76 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Celcuity Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Celcuity Inc

RSI

Intraday RSI14 chart for Celcuity Inc

Last 10 Buy & Sell Signals For CELC

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:34sell$14.46N/AActive
Profile picture for
            Celcuity Inc

CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Last 10 Buy Signals

Date Signal @
WEGLDUSDMar 28 - 05:4961.23
WBETHUSDMar 28 - 05:493 698.87
FOLDUSDMar 28 - 05:5020.98
BONDUSDMar 28 - 05:466.14
RDNTUSDMar 28 - 05:440.335
SETH2USDMar 28 - 05:443 496.64
SAVAXUSDMar 28 - 05:4461.90
GNSUSDMar 28 - 05:445.11
INDEXUSDMar 28 - 05:445.94
FNSAUSDMar 28 - 05:4435.73

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.